Evolus [EOLS] vs Zoetis [ZTS] Detailed Stock Comparison
Evolus
NASDAQ
Loading...
Zoetis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Evolus wins in 6 metrics, Zoetis wins in 12 metrics, with 0 ties. Zoetis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Evolus | Zoetis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -7.29 | 27.31 | Evolus |
| Price-to-Book Ratio | -20.43 | 14.58 | Evolus |
| Debt-to-Equity Ratio | -7.80 | 145.63 | Evolus |
| PEG Ratio | 31.85 | 23.99 | Zoetis |
| EV/EBITDA | -14.06 | 18.82 | Evolus |
| Profit Margin (TTM) | -22.31% | 27.12% | Zoetis |
| Operating Margin (TTM) | -20.36% | 38.11% | Zoetis |
| EBITDA Margin (TTM) | N/A | 38.11% | N/A |
| Return on Equity | -18,729.61% | 52.09% | Zoetis |
| Return on Assets (TTM) | -11.06% | 15.11% | Zoetis |
| Free Cash Flow (TTM) | $-22.82M | $2.30B | Zoetis |
| Dividend Yield | N/A | 1.11% | N/A |
| 1-Year Return | -53.16% | -18.39% | Zoetis |
| Price-to-Sales Ratio (TTM) | 1.48 | 7.29 | Evolus |
| Enterprise Value | $494.85M | $72.76B | Zoetis |
| EV/Revenue Ratio | 1.78 | 7.84 | Evolus |
| Gross Profit Margin (TTM) | 65.31% | 71.98% | Zoetis |
| Revenue per Share (TTM) | $4 | $21 | Zoetis |
| Earnings per Share (Diluted) | $-0.97 | $5.57 | Zoetis |
| Beta (Stock Volatility) | 1.12 | 0.91 | Zoetis |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Evolus vs Zoetis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Evolus | -2.64% | -31.95% | -33.59% | -48.38% | -53.70% | -45.36% |
| Zoetis | 1.51% | -3.12% | -7.42% | -5.31% | -14.28% | -9.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Evolus | -53.16% | -36.77% | 63.17% | -47.94% | -47.94% | -47.94% |
| Zoetis | -18.39% | -15.59% | -7.24% | 205.07% | 375.27% | 375.27% |
Performance & Financial Health Analysis: Evolus vs Zoetis
| Metric | EOLS | ZTS |
|---|---|---|
| Market Information | ||
| Market Cap | $412.05M | $67.73B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,887,200 | 3,477,390 |
| 90 Day Avg. Volume | 1,488,497 | 3,122,150 |
| Last Close | $5.91 | $167.10 |
| 52 Week Range | $5.85 - $17.82 | $139.70 - $200.33 |
| % from 52W High | -66.84% | -16.59% |
| All-Time High | $39.50 (Jun 04, 2018) | $249.27 (Dec 27, 2021) |
| % from All-Time High | -85.04% | -32.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.01% |
| Quarterly Earnings Growth | 0.04% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | -0.22% | 0.27% |
| Operating Margin (TTM) | -0.20% | 0.38% |
| Return on Equity (TTM) | -187.30% | 0.52% |
| Debt to Equity (MRQ) | -7.80 | 145.63 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.29 | $10.44 |
| Cash per Share (MRQ) | $0.96 | $3.91 |
| Operating Cash Flow (TTM) | $-41,337,000 | $2.94B |
| Levered Free Cash Flow (TTM) | $-22,250,250 | $2.30B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.11% |
| Last 12-Month Dividend | N/A | $1.86 |
Valuation & Enterprise Metrics Analysis: Evolus vs Zoetis
| Metric | EOLS | ZTS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -7.29 | 27.31 |
| Forward P/E | 31.85 | 23.99 |
| PEG Ratio | 31.85 | 23.99 |
| Price to Sales (TTM) | 1.48 | 7.29 |
| Price to Book (MRQ) | -20.43 | 14.58 |
| Market Capitalization | ||
| Market Capitalization | $412.05M | $67.73B |
| Enterprise Value | $494.85M | $72.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.78 | 7.84 |
| Enterprise to EBITDA | -14.06 | 18.82 |
| Risk & Other Metrics | ||
| Beta | 1.12 | 0.91 |
| Book Value per Share (MRQ) | $-0.29 | $10.44 |
Financial Statements Comparison: Evolus vs Zoetis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | EOLS | ZTS |
|---|---|---|
| Revenue/Sales | $69.39M | $2.22B |
| Cost of Goods Sold | $24.07M | $622.00M |
| Gross Profit | $45.32M | $1.60B |
| Research & Development | $1.84M | $157.00M |
| Operating Income (EBIT) | $-14.12M | $846.00M |
| EBITDA | $-7.84M | $991.00M |
| Pre-Tax Income | $-17.09M | $810.00M |
| Income Tax | $53,000 | $179.00M |
| Net Income (Profit) | $-17.14M | $631.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | EOLS | ZTS |
|---|---|---|
| Cash & Equivalents | $67.89M | $1.72B |
| Total Current Assets | $131.72M | $5.88B |
| Total Current Liabilities | $56.23M | $3.39B |
| Long-Term Debt | $128.23M | $5.40B |
| Total Shareholders Equity | $-6.60M | $4.66B |
| Retained Earnings | $-628.29M | $12.38B |
| Property, Plant & Equipment | $7.40M | $6.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | EOLS | ZTS |
|---|---|---|
| Operating Cash Flow | $-2.41M | $567.00M |
| Capital Expenditures | $-319,000 | N/A |
| Free Cash Flow | $-17.49M | $438.00M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-443.00M |
Short Interest & Institutional Ownership Analysis
| Metric | EOLS | ZTS |
|---|---|---|
| Shares Short | 12.63M | 7.85M |
| Short Ratio | 14.11 | 2.67 |
| Short % of Float | 0.20% | 0.02% |
| Average Daily Volume (10 Day) | 2,887,200 | 3,477,390 |
| Average Daily Volume (90 Day) | 1,488,497 | 3,122,150 |
| Shares Outstanding | 63.50M | 448.47M |
| Float Shares | 54.36M | 444.39M |
| % Held by Insiders | 0.05% | 0.00% |
| % Held by Institutions | 0.86% | 0.96% |
Dividend Analysis & Yield Comparison: Evolus vs Zoetis
| Metric | EOLS | ZTS |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.86 |
| Last 12-Month Dividend Yield | N/A | 1.11% |
| 3-Year Avg Annual Dividend | N/A | $1.63 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $4.90 |
| Ex-Dividend Date | N/A | Apr 21, 2025 |